ABCL earnings call for the period ending September 30, 2024.
With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.
ABCL earnings call for the period ending June 30, 2024.
Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Wall Street analysts say this drug developer can more than double your money.
ABCL earnings call for the period ending March 31, 2024.
The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven...
ABCL earnings call for the period ending December 31, 2023.
Healthcare stocks have underperformed in 2023, but that is expected to change this year.